AOPNS-042 is under clinical development by Aodh Lifesciences and currently in Phase I for Unspecified Infectious Diseases. According to GlobalData, Phase I drugs for Unspecified Infectious Diseases does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the AOPNS-042 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AOPNS-042 overview
AOPNS-042 is under development for the treatment of post surgery nasal infections. The drug candidate is administered through inhalational route in the form of nasal spray.
Aodh Lifesciences overview
Aodh Lifesciences Private Limited is a medical research company that develop oxygen nano-bubbles to deliver intravenous oxygen.
For a complete picture of AOPNS-042’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.